- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Daniel F. Hayes, MD
Clinical Director, Breast Oncology Program
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan
Ann Arbor, Michigan
Goal: To identify and validate clinical biomarkers to inform patient care and the design of future clinical trials.
Impact: Dr. Hayes is collecting specimens such as breast cancer tissue and blood samples from consenting patients who participate in prospective clinical trials. His analysis of these materials can be used to predict how patients will respond to a particular therapy.
What’s next: He and his team will continue to collect and analyze patient samples to discover new biomarkers and gain insight into the mechanisms of response and resistance to treatment—information that would improve both patient care and the design of future clinical investigations.
Clinical trials are crucial to advancing breast cancer care, and they also provide researchers with a large resource of de-identified patient samples from participants who consent to sharing their blood, tissues, DNA, etc. Dr. Hayes and his team are collecting these samples in order to discover biomarkers that can be used to match targeted treatments with each patient’s tumor. He is leading efforts by one of the major national cooperative groups to conduct these kinds of studies.
Full Research Summary
Research area: Collecting and analyzing clinical samples to identify biomarkers to inform patient care and the design of future clinical trials.
Impact: Dr. Hayes’ study of breast cancer tissues, blood, serum, and DNA from patients who participated in clinical trials is allowing him to validate biomarkers that may change prognosis or predict whether a patient will or will not benefit from a particular therapy, and may even predict side effects.
What he’s accomplished so far: The clinical specimens he has collected have been used in a variety of projects, the results of which provided insight into mechanisms of response and resistance. He works with clinical trialists from U.S. clinical trial cooperative groups, as well as European counterparts conducting correlative studies within ongoing clinical trials. Examples of his collaborations include SWOG studies in triple negative breast cancer and multiple studies looking at immune signature and other biomarkers both in Europe and the U.S.
What’s next: Dr. Hayes will continue to collect clinical specimens that can be used to conduct correlative science studies of new or promising tumor biomarkers.
Daniel Hayes, MD, is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center (UMCCC) and the Stuart B. Padnos Professor of Breast Cancer Research. He received AB (1974) and MS (1977) degrees at Indiana University, his MD from the Indiana University School of Medicine (1979), a residency in Internal Medicine at the UTHSC, Dallas, Texas (Parkland Memorial Hospital, 1979-1982), and a fellowship in Medical Oncology at Harvard’s Dana Farber Cancer Institute (DFCI, 1982–1985). From 1992–1996, he was Medical Director of the Breast Evaluation Center at DFCI. In 1996, he moved to the Georgetown University Lombardi Cancer Center, and he joined the UMCCC in 2001. Dr. Hayes has a national and international reputation in the field of experimental therapeutics targeted to breast cancer, working on serum and tissue markers such as HER-2, circulating tumor cells and pharmacogenomics which have prognostic and/or predictive value in the treatment of breast cancer. In June 2015 he became president-elect of the American Society of Clinical Oncology.